AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2181334
Drug: Nimodipine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (both doses) in patients with Hunt and Hess grades I to III
Trial: 473853
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg Metoprolol
Trial: 473853
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg Pindolol
Trial: 27864127
Drug: latiglutenase 100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: latiglutenase 100, 300, 450, 600, or 900 mg daily for 12 or 24 weeks
Trial: 12467956
Drug: Sucrose solution
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose solution swallowed (0, 5, 10, 20, and 40%)
Trial: 12467956
Drug: Sucrose solution
RxNorm normalized name: TootSweet 24% Oral Sucrose Solution
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose solution spit (0, 5, 10, 20, and 40%)
Trial: 12467956
Drug: Fear to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fear to swallow sucrose solution (covariate)
Trial: 7840322
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplements
Trial: 2206140
Drug: Alpha‐tocopherol‐enriched coconut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha‐tocopherol‐enriched coconut oil supplements (placebo)
Trial: 7227621
Drug: Prothiaden (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothiaden (75 mg)
Trial: 7227621
Drug: Lentizol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lentizol (50 mg)
Trial: 25953494
Drug: Shock wave
RxNorm normalized name: ELECTRODE GEL,H-WAVE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shock wave therapy (ESWT)
Trial: 7553070
Drug: injections of
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injections of allergen-specific antibody complexes
Trial: 2187982
Drug: Exercise plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise plus relaxation and breathing therapy (Treatment A)
Trial: 2187982
Drug: Exercise training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise training only (Treatment B)
Trial: 31498113
Drug: 12-month DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-month DAPT followed by 12-month aspirin monotherapy (control)
Trial: 27583931
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia (Group C)
Trial: 27583931
Drug: Total intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total intravenous anesthesia with hypertension (Group D)
Trial: 23225838
Drug: Carbamazepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (100 mg, 3 times a day for 60 days) + Botulinum toxin A (local intramuscular injections)
Trial: 23225838
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A (local intramuscular injections only)
Trial: 12502011
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg mirtazapine
Trial: 2562333
Drug: Omeprazole (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (10 mg or 20 mg each morning for 2 weeks)
Trial: 2562333
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg twice daily for 2 weeks)
Trial: 2562333
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg nightly for 1 year)
Trial: 1179368
Drug: Radiotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy combined with chemotherapy
Trial: 29858027
Drug: Osimertinib (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osimertinib (80 mg/day)
Trial: 29858027
Drug: Docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (75 mg/m2) and Bevacizumab (7.5 mg/kg) every 21 days
Trial: 27250219
Drug: Beauty care
RxNorm normalized name: ALCOHOL 60.15 mL in 100 mL TOPICAL GEL [Henkel Beauty Care Professional]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beauty care program (two training sessions per month for 3 months and daily facial skin care)
Trial: 24184299
Drug: Synbiotic supplement
RxNorm normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synbiotic supplement for eight weeks
Trial: 18520184
Drug: Endolymphatic sac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endolymphatic sac drainage and steroid instillation (G-I)
Trial: 18520184
Drug: Endolymphatic sac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endolymphatic sac drainage without steroid instillation (G-II)
Trial: 18520184
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (G-III)
Trial: 10725767
Drug: DHA supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplement (200 mg DHA/day)
Trial: 10725767
Drug: (13)C-labeled linoleic
RxNorm normalized name: linoleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (13)C-labeled linoleic acid (1 mg/kg body weight)
Trial: 8542857
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia with bupivacaine-adrenaline before starting surgery and a booster dose after 60 min
Trial: 8542857
Drug: Epidural dose
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural dose of bupivacaine-adrenaline at 60 min
Trial: 1781803
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 500 mg with glycine 250 mg
Trial: 1781803
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 500 mg without glycine
Trial: 6168829
Drug: Prenalterol (0.1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol (0.1, 0.25, and 0.5 mg)
Trial: 6168829
Drug: Prenalterol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol (10 times higher dose after beta-blockers)
Trial: 6168829
Drug: Metoprolol (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (20 mg)
Trial: 22192847
Drug: MF59-H5N1 vaccine
RxNorm normalized name: influenza A virus (H5N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-H5N1 vaccine
Trial: 22867771
Drug: Sensor-augmented pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented pump therapy (SAPT)
Trial: 18984887
Drug: 12-week buprenorphine-naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12-week buprenorphine-naloxone (up to 24 mg per day for 9 weeks, then tapered to week 12)
Trial: 18984887
Drug: Detox group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detox group (14-day taper, up to 14 mg per day)
Trial: 15974485
Drug: Gui‐zhi‐fu‐ling‐wan (herbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gui‐zhi‐fu‐ling‐wan (herbal therapy)
Trial: 27307358
Drug: Combined group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined group (IV administration of 15 mg/kg of TXA combined with topical administration of 1 g/100 mL of TXA)
Trial: 27307358
Drug: Single IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV group (IV administration of 15 mg/kg of TXA)
Trial: 14687987
Drug: IFN-alpha maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN-alpha maintenance therapy (41 patients)
Trial: 11151453
Drug: Trastuzumab as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab as a single agent
Trial: 25557693
Drug: Test meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test meal (240 mL, 12 kcal broth)
Trial: 17473091
Drug: Head cooling
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Head cooling for 72 hours, starting within 6 hours after birth (rectal temperature maintained at 34.5 +/- 0.5 degrees C)
Trial: 1091397
Drug: 0.5‐mg doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐mg doses of digoxin from lot 1
Trial: 1091397
Drug: 0.5‐mg doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐mg doses of digoxin from lot 2
Trial: 1091397
Drug: 0.5‐mg doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐mg doses of digoxin from lot 3
Trial: 1091397
Drug: 0.5‐mg doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐mg doses of digoxin from lot 4
Trial: 1091397
Drug: 0.5‐mg doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5‐mg doses of digoxin from one lot taken twice
Trial: 31378395
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (500 mg twice a day, adjustable to a maximum of four tablets and a minimum of one tablet a day)
Trial: 31378395
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two oral tablets a day)
Trial: 28514344
Drug: Erbium laser
RxNorm normalized name: erbium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erbium laser treatment
Trial: 23975856
Drug: Conventional surgical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional surgical treatment (Control)
Trial: 17723882
Drug: Serum IL-15
RxNorm normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum IL-15 levels less than 3.0 pg/mL
Trial: 17723882
Drug: Serum IL-15
RxNorm normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum IL-15 levels between 3.0-5.3 pg/mL
Trial: 17723882
Drug: Serum IL-15
RxNorm normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum IL-15 levels greater than or equal to 5.3 pg/mL
Trial: 17723882
Drug: Serum IL-15
RxNorm normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum IL-15 levels less than 5.5 pg/mL
Trial: 17723882
Drug: Serum IL-15
RxNorm normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum IL-15 levels between 5.5-9.0 pg/mL
Trial: 17723882
Drug: Serum IL-15
RxNorm normalized name: Humax-IL 15
DrugBank: Ordesekimab (DB16649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum IL-15 levels greater than or equal to 9.0 pg/mL
Trial: 15226326
Drug: Sequential doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential doxorubicin followed by docetaxel (A‐‐>T)
Trial: 7832682
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (GaAlAs laser)
Trial: 3276193
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment with 300 mg doxycycline
Trial: 28402245
Drug: Levothyroxine (starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levothyroxine (starting dose of 50 μg daily, or 25 μg if body weight <50 kg or with coronary heart disease)
Trial: 10201430
Drug: Medication withdrawn
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication withdrawn in one patient
Trial: 31535099
Drug: Resorbable poly‐D‐L‐lactide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resorbable poly‐D‐L‐lactide foil fixed at a distance (SonicWeld Rx shell technique [SWST])
Trial: 19198801
Drug: Brace treatment
RxNorm normalized name: Brace Relief
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brace treatment (Dresden scoliosis orthosis)
Trial: 19198801
Drug: Noncompliant group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncompliant group (no brace treatment)
Trial: 19198801
Drug: Compliant group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compliant group (brace treatment)
Trial: 16937304
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (estramustine phosphate + endocrine therapy)
Trial: 16937304
Drug: Endocrine monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine monotherapy
Trial: 15665929
Drug: Beta-adrenoblockers and
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-adrenoblockers and angiotensin-converting enzyme inhibitors
Trial: 9164179
Drug: Filgrastim 5
RxNorm normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Filgrastim 5 micrograms/kg/d SC bolus injection
Trial: 9164179
Drug: Filgrastim 10
RxNorm normalized name: pegfilgrastim 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Filgrastim 10 micrograms/kg/d SC continuous infusion
Trial: 7693314
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (topical glucocorticoid)
Trial: 3297278
Drug: Maintenance treatment
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance treatment with BCNU, cyclophosphamide, vincristine, and prednisone (BCVP) given every 6 weeks for an additional 18 months
Trial: 17699816
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further therapy (control group)
Trial: 18330846
Drug: Lamotrigine (LTG)
RxNorm normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lamotrigine (LTG) monotherapy
Trial: 27218676
Drug: GS-5745 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-5745 (multiple doses: 0.3, 1.0, 2.5 or 5.0 mg/kg IV every 2 weeks or 150 mg SC weekly)
Trial: 27218676
Drug: GS-5745 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GS-5745 (multiple doses)
Trial: 22195358
Drug: Nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol (5 mg/day for 3 weeks, then 10 mg/day)
Trial: 19758285
Drug: Group 1
RxNorm normalized name: Chlamydophila psittaci biogroup 1 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1 (G1) - informed treatment
Trial: 19758285
Drug: Group 2
RxNorm normalized name: Chlamydophila psittaci biogroup 2 Ab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2 (G2) - informed possible active drug or placebo
Trial: 29631553
Drug: 10-week oral
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10-week oral estrogen replacement (combination of ethinyl estradiol 0.03 mg and dienogest 2 mg)
Trial: 16873437
Drug: Prebiotic oligosaccharides
RxNorm normalized name: chitosan oligosaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prebiotic oligosaccharides (0.8 g/100 ml)
Trial: 31789451
Drug: Vildagliptin (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (50 mg twice)
Trial: 26642301
Drug: Saxagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saxagliptin (5 mg)
Trial: 20970963
Drug: 0.5% PVP-I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% PVP-I solution (Arakeri's iodine solution)
Trial: 11763939
Drug: Oral‐B CrossAction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral‐B CrossAction toothbrush
Trial: 7935276
Drug: N-acetylcysteine (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (600 mg a day for two years)
Trial: 7935276
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drugs (control group)
Trial: 30629306
Drug: Swallowing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing therapy program initiated within 1 year post-radiotherapy
Trial: 30629306
Drug: Swallowing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swallowing therapy program initiated after 2 years post-radiotherapy
Trial: 8679463
Drug: No perioperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No perioperative chemotherapy
Trial: 8790128
Drug: Blood lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood lead levels greater than 0.96 mumol/L (20 micrograms/dL)
Trial: 8790128
Drug: Blood lead
RxNorm normalized name: lead
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood lead levels greater than 0.48 mumol/L (10 micrograms/dL)
Trial: 1282619
Drug: Nisoldipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nisoldipine (10 mg twice daily)
Trial: 6433495
Drug: BCAA enriched
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BCAA enriched solution containing 50% of amino acids as BCAA
Trial: 6433495
Drug: Complete feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complete feeding solution containing 15.6% of amino acids as BCAA
Trial: 10210384
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg furosemide
Trial: 8533565
Drug: Misoprostol (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (administered orally 17 hours before vacuum curettage)
Trial: 8533565
Drug: Misoprostol (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misoprostol (administered orally 10 hours before vacuum curettage)
Trial: 30293352
Drug: Dexmedetomidine (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (loading dose of 1.0 μg/kg, followed by continuous infusion of 0.5 μg·kg(‐1)·h(‐1) until 20 min before the end of operation)
Trial: 23085116
Drug: Graded exercise
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graded exercise treatment (GET)
Trial: 21389329
Drug: Transdermal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal fluid (TDF) sampling following acute plyometric exercise
Trial: 21389329
Drug: Transdermal fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal fluid (TDF) sampling following 60 min of cycling exercise at 60% Vo(2)(peak)
Trial: 18513462
Drug: Varenicline (0.5-2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (0.5-2.0 mg/day)
Trial: 14570652
Drug: IV saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline 5 mL (Group I)
Trial: 14570652
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of IV pantoprazole (Group II)
Trial: 14570652
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of IV ranitidine (Group III)
Trial: 11218969
Drug: Cost-effectiveness of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost-effectiveness of Atorvastatin
Trial: 2458198
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (2 x 2 mg)
Trial: 1563131
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with propranolol 20 mg tid and diltiazem 60 mg tid
Trial: 362831
Drug: i.v. L-tryptophan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. L-tryptophan
Trial: 31295165
Drug: SBIRT (Substance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SBIRT (Substance Use Screening, Brief Intervention, and Referral to Treatment)
Trial: 22836861
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral refeeding (EORF)
Trial: 25441594
Drug: Conventional oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional oral refeeding (CORF)
Trial: 25022371
Drug: Modified oral
RxNorm normalized name: Food Starch, Modified Oral Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified oral brush biopsy
Trial: 17322145
Drug: Once-daily mesalazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily mesalazine (1 x 4 g/d)
Trial: 17322145
Drug: Twice-daily mesalazine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily mesalazine (2 x 2 g/d)
Trial: 11882333
Drug: 25 mg/day
RxNorm normalized name: estradiol 0.025 MG/Day Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg/day TRF25
Trial: 11882333
Drug: 50 mg/day
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/day TRF25
Trial: 11882333
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day TRF25
Trial: 11882333
Drug: 200 mg/day
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/day TRF25
Trial: 9835980
Drug: Midazolam (0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.07 mg.kg‐1, IM)